Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
InnoPCV + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Innovac Therapeutics
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
InnoPCV + PD-1 inhibitor is an investigational combination immunotherapy regimen being evaluated for the treatment of advanced solid tumors. The regimen consists of InnoPCV, an individualized neoantigen-based mRNA cancer vaccine developed by InnoSera (Beijing) Biotechnology, and a programmed cell death protein 1 (PD-1) checkpoint inhibitor. InnoPCV is designed by sequencing a patient's tumor to identify unique neoantigens, which are then encoded into an mRNA platform to stimulate a personalized T-cell response. The addition of a PD-1 inhibitor is intended to synergistically enhance this immune response by blocking the inhibitory PD-1/PD-L1 pathway, thereby preventing T-cell exhaustion and promoting sustained anti-tumor activity. This combination is currently undergoing Phase Ia/Ib clinical testing to assess its safety, tolerability, and preliminary efficacy in patients with various advanced solid malignancies.
- Other names
- InnoPCV + PD-1InnoPCV in combination with PD-1
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on InnoPCV + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnoPCV + PD-1 inhibitor.